Once-daily dosing...improves convenience

Dong-A ST disclosed on November 2 that Stillen Q tablets, a treatment for acute and chronic gastritis containing a concentrated extract of mugwort (Artemisia leaves) made with ethanol, had received domestic marketing approval from the Ministry of Food and Drug Safety. The approval was granted on October 30, about six months after the company applied on April 16.

Dong-A ST's "Stillen Q Tablets" Receive Domestic Marketing Approval View original image

Stillen Q tablets contain the same active ingredient as Dong-A ST's gastritis treatment Stillen tablets, but are designed to reduce the dosage frequency to once a day. Dong-A ST expects the reduced frequency to make the medicine more convenient for patients to take and improve medication adherence.


Stillen is a natural medicine whose active ingredient is an extract of Artemisia leaves. Dong-A ST developed it over nine years through industry-academia-research collaboration, investing about 18 billion won. Annual prescription sales exceeded 90 billion won in 2011, and cumulative sales since its launch have reached 1 trillion won.


The company first launched Stillen tablets in 2002, to be taken three times a day, and introduced Stillen 2X tablets in 2015, reducing the dosage frequency to twice a day. Stillen Q tablets were developed to take this a step further and improve convenience by requiring just one dose a day.



The launch date has not yet been decided. A Dong-A ST official said, "We will consider whether to launch the product in the future, taking into account the domestic market environment, business prospects and other factors."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing